树突状细胞在肿瘤免疫治疗中的临床应用进展  

Advances in Clinical Application of Dendritic Cells in Tumor Immunotherapy

作　　者：曾林梅 龙金华[2] 金风[2] ZENG Linmei;LONG Jinhua;JIN Feng(Clinical School of Medicine,Guizhou Medical University,Guiyang 550000,China;Department of Head and Neck Oncology,Guizhou Cancer Hospital,Guiyang 550000,China)

机构地区：[1]贵州医科大学临床医学院,贵阳550000 [2]贵州省肿瘤医院头颈肿瘤科,贵阳550000

出　　处：《医学综述》2020年第23期4629-4633,4642,共6页Medical Recapitulate

基　　金：国家自然科学基金(81560437);贵州省科技计划项目(黔科合基础〔2019〕1266)。

摘　　要：树突状细胞(DC)是目前公认的最有效的抗原呈递细胞,在介导固有免疫应答和诱导适应性免疫应答中起关键作用,可以诱导肿瘤免疫耐受。基于DC的免疫疗法是利用患者自身免疫系统的潜力消除转移性、难治性恶性肿瘤中的肿瘤细胞。许多DC疫苗已进行了临床测试,且具有免疫原性,在某些情况下与临床结果相关。以DC为基础的肿瘤免疫治疗相关的临床研究在国内外不断开展,体现了肿瘤免疫治疗在恶性肿瘤治疗中的强大优势。Dendritic cell(DC)are the most effective antigen presenting cells,which play a key role in mediating innate immune response and inducing adaptive immune response,and can induce tumor immune tolerance.DC-based immunotherapy is an approved approach that utilizes the potential of a patient′s own immune system to eliminate tumor cells from metastatic,refractory cancers.Many DC vaccines have been tested in clinical trials and have been shown to be immunogenic and,in some cases,relevant to the clinical outcomes.The clinical research on DC-based tumor immunotherapy has been carried out continuously at home and abroad,showing the powerful advantages of tumor immunotherapy for malignancies.

关 键 词：肿瘤 树突状细胞 抗原呈递细胞 免疫耐受 免疫治疗 

分 类 号：R730.5[医药卫生—肿瘤]